Base rate computed from analyst-asserted responds_to: edges in the reverse direction (target-country → issuer-country) for prior issuer-actions on the same target. Modal type + lag percentiles only — not a model output. Treat as a historical anchor for sizing counter-response scenarios, not a forecast in itself.

Theme momentum

1themes this action belongs to

US counter-narcotics sanctions architecture — EO 14059 and drug-trade regulatory perimeter

0 filings in 90d

→ steady

On 3 September 2025, the U.S. Treasury's Office of Foreign Assets Control (OFAC) designated Guangzhou Tengyue Chemical Co., Ltd., a China-based chemical manufacturer, along with two of its representatives, Huang Xiaojun and Huang Zhanpeng, pursuant to Executive Order 14059 for materially contributing to the international proliferation of illicit drugs. The company was found to have manufactured and sold synthetic opioids — including nitazenes — and analgesic cutting agents such as xylazine and medetomidine to U.S. buyers. The designation blocks all U.S.-person property and transactions involving the three designated persons and any entity 50%-or-more owned by them; the FBI simultaneously announced a related federal indictment against Guangzhou Tengyue, the two individuals, and roughly 22 other China-based individuals and businesses for conspiracy to commit drug trafficking.

Analyst notesShow

Mechanism

OFAC designated one company and two named individuals under E.O. 14059 (the counter-illicit-drug-trade sanctions authority): Guangzhou Tengyue Chemical Co., Ltd. and Huang Xiaojun for having "engaged in, or attempted to engage in, activities ... that have materially contributed to ... the international proliferation of illicit drugs or their means of production," and Huang Zhanpeng for providing material/financial support to the company. The investigation (DEA Tampa "CHEMEX" + FBI Cincinnati, opened January 2024) documented Guangzhou Tengyue selling protonitazene and related nitazene synthetic opioids, plus the veterinary sedative-turned-cutting-agent xylazine and its analogue medetomidine, to U.S. buyers — including a 2023 sale of a kilogram of protonitazene. A parallel FBI indictment names ~22 additional China-based individuals/businesses and 3 U.S.-based co-conspirators under 21 U.S.C. §846.

This is a narrow, single-network designation (1 company + 2 individuals), not a sectoral or country-wide chemical-trade control — it freezes only the named persons' U.S.-reachable assets and blocks U.S.-person dealings with them, with no broader precursor-chemical export-licensing regime attached (contrast the 2025-11-10 MOFCOM precursor-chemicals licensing action, which is a systemic Chinese-side control).

Downstream implications

No direct trade/tariff or supply-chain exposure for legitimate chemical

manufacturers; scope is limited to the designated persons and any entity they own 50%+ of.

Reinforces the fentanyl-precursor track record cited as justification for

the broader 2025-02-01 US fentanyl tariffs on China (2025-02-01-us-trump-fentanyl-tariffs-canada-mexico-china), though this action itself carries no tariff or licensing mechanism.

Watch for follow-on OFAC designations from the same DEA CHEMEX

investigation network (~22 other named China-based entities/individuals in the FBI indictment were not sanctioned in this action).

Open questions

Whether any of the ~22 additional indicted China-based individuals/entities

receive their own OFAC designation in a later action.

Whether Guangzhou Tengyue appears on China's own precursor-chemical control

lists (cross-check against MOFCOM precursor licensing actions).

Sources

Primary: US Treasury press release — Treasury Sanctions China-Based Chemical Company to Combat Synthetic Opioid Trafficking

Secondary: Global Trade Alert — state act 94260

Loading…

Mechanism

Downstream implications

No direct trade/tariff or supply-chain exposure for legitimate chemical

manufacturers; scope is limited to the designated persons and any entity they own 50%+ of.

Reinforces the fentanyl-precursor track record cited as justification for

the broader 2025-02-01 US fentanyl tariffs on China (2025-02-01-us-trump-fentanyl-tariffs-canada-mexico-china), though this action itself carries no tariff or licensing mechanism.

Watch for follow-on OFAC designations from the same DEA CHEMEX

investigation network (~22 other named China-based entities/individuals in the FBI indictment were not sanctioned in this action).